KRAS and familial pancreatic carcinoma: Treatment of pancreatic cancer cell line with XMD8-92, a kinase inhibitor, led to similar effects as downregulation of DCLK1, upregulation of miR-143/145, miR-144, miR-200a, b, c, and let-7, and a decrease in the expression of proliferative, metastatic, and angiogenic markers (c-MYC, KRAS, NOTCH1, ZEB1, ZEB2, SNAIL, SLUG, OCT4, SOX2, NANOG, KLF4, LIN28, VEGFR1, and VEGFR2) [163].